SPAC | Jotup

WALD INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Waldencast plc (WALD) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on:

Monday, August 28, 2023

SPAC, Bank statement, Person, FYE, Sale, Cosmeceutical, Hagens Berman, SAN, WALD, Book, Cryptocurrency, Pharmaceutical industry, Zein E. Obagi

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .

Key Points:

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .
31, 2022 and June 30, 2022 as a result of improper revenue recognition involving Obagi sales to its Southeast Asia distributor.
“We’re focused on investors’ losses and whether Waldencast cooked its books,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Waldencast and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Retrieved on:

Monday, August 28, 2023

SPAC, Charles River Laboratories, Partnership, PIPE, Incyte, MDNA, Zenon Caravella, Editas Medicine, Tango, Syracuse University, Drug discovery, CFO, Johnson & Johnson, Management, Pharmaceutical industry, Finance

TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna’s financial strategy to support the Company’s growth. This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer.

Key Points:

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations
Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem
TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO).
In this position, Mr. Caravella will lead Medicenna’s financial strategy to support the Company’s growth.
This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer.
He brings a wealth of financial leadership experience to Medicenna, having successfully navigated the complex biotech financial landscape and driven growth strategies for prominent life science corporations,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.

ORGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Origin Materials, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Monday, August 28, 2023

SPAC, CASE, Origin, Carbon, Acquisition, SAN, Robbins Geller Rudman & Dowd LLP, Biomass, News, Tobacco, Cryptocurrency, Pharmaceutical industry

), the Origin Materials class action lawsuit charges Origin Materials and certain of its top officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the Origin Materials class action lawsuit charges Origin Materials and certain of its top officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the Origin Materials class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the Origin Materials class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Origin Materials class action lawsuit.

Mobile Infrastructure Corporation Completes Public Listing Following Merger with Fifth Wall Acquisition Corp. III

Retrieved on:

Monday, August 28, 2023

The transaction valued the equity of Mobile at $15.00 per share versus its published 2022 Net Asset Value (“NAV”) of $14.76 per share.

Key Points:

The transaction valued the equity of Mobile at $15.00 per share versus its published 2022 Net Asset Value (“NAV”) of $14.76 per share.
Mobile Infrastructure Corporation’s common stock commenced trading on the New York Stock Exchange American under the ticker “BEEP” on August 28, 2023.
Manuel Chavez, CEO and Chairman of Mobile Infrastructure stated, “Public listing is an important milestone in our growth trajectory.
Brad Greiwe, Co-Founder and Managing Partner at Fifth Wall, commented, “We are excited to have completed the merger with Mobile Infrastructure in a transaction that very clearly aligns the interests of all stakeholders.

ORGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Origin Materials, Inc. Investors with Substantial Losses Have Opportunity to Lead the Origin Materials Class Action Lawsuit

Retrieved on:

Friday, August 25, 2023

Class Action Lawsuit, Professional Services, Legal, SPAC, CASE, Origin, Carbon, Acquisition, Biomass, News, Tobacco, Cryptocurrency, Pharmaceutical industry

), the Origin Materials class action lawsuit charges Origin Materials and certain of its top officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the Origin Materials class action lawsuit charges Origin Materials and certain of its top officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the Origin Materials class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the Origin Materials class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Origin Materials class action lawsuit.

Logiq Reports Continued Progress with Major Corporate Initiatives, with Strong Outlook for 2023 on Track

Retrieved on:

Friday, August 25, 2023

SPAC, IPO, ABRI, DLQ, SME, African, King's Cross, London, Acquisition, OTCQX, Form, SE, Growth, Security (finance), Retail, Pharmaceutical industry, Southeast Asia

A new major consumer product client signed in November 2022 has transitioned to Logiq’s programmatic advertising platform which should generate high-margin revenues.

Key Points:

A new major consumer product client signed in November 2022 has transitioned to Logiq’s programmatic advertising platform which should generate high-margin revenues.
The associated credit facility to enable the ramp up of this business is dependent upon a listing on a senior stock exchange.
DataLogiq (DLQ) Subsidiary SPAC Merger: The company has continued to progress toward the completion of the SPAC merger.
Our goal with the acquisition of such targets are for Logiq to realize revenues well in excess of current levels.”

LIFW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MSP Recovery, Inc. f/k/a Lionheart Acquisition Corp. II Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Thursday, August 24, 2023

Fla.), the MSP Recovery class action lawsuit charges MSP Recovery and certain of MSP Recovery and Lionheart’s top executives with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.

Key Points:

Fla.), the MSP Recovery class action lawsuit charges MSP Recovery and certain of MSP Recovery and Lionheart’s top executives with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the MSP Recovery class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the MSP Recovery class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the MSP Recovery class action lawsuit.

HOLLEY ALERT: Bragar Eagel & Squire, P.C. is Investigating Holley Inc. on Behalf of Holley Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, August 24, 2023

Class Action Lawsuit, Professional Services, Legal, Telephone, SPAC, P.C, Jeanne Eagels (film), NYSE, Security (finance)

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Holley Inc. (“Holley” or the “Company”) (NYSE: HLLY) on behalf of Holley stockholders.

Key Points:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Holley Inc. (“Holley” or the “Company”) (NYSE: HLLY) on behalf of Holley stockholders.
Our investigation concerns whether Holley has violated the federal securities laws and/or engaged in other unlawful business practices.
On July 16, 2021, Empower Ltd., previously operating as a SPAC, completed a business combination with Holley Intermediate Holdings, Inc.
The combined company became Holley and its common stock and warrants trade on the NYSE under the ticker symbols “HLLY” and “HLLY WT,” respectively.

LIFW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MSP Recovery, Inc. f/k/a Lionheart Acquisition Corp. II Investors with Substantial Losses Have Opportunity to Lead the MSP Recovery Class Action Lawsuit

Retrieved on:

Thursday, August 24, 2023

Robbins Geller Rudman & Dowd LLP announces that (i) purchasers or acquirers of MSP Recovery, Inc. f/k/a Lionheart Acquisition Corp. II.

Key Points:

Robbins Geller Rudman & Dowd LLP announces that (i) purchasers or acquirers of MSP Recovery, Inc. f/k/a Lionheart Acquisition Corp. II.
Fla.), the MSP Recovery class action lawsuit charges MSP Recovery and certain of MSP Recovery and Lionheart’s top executives with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.
The lead plaintiff can select a law firm of its choice to litigate the MSP Recovery class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the MSP Recovery class action lawsuit.

SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company

Retrieved on:

Wednesday, August 23, 2023

SPAC, Mayo, SEPA, PIPE, Perspiration, OTCQB, Acquisition, Clinical professor, EDEN, FDA, Security (finance), Cryptocurrency

· SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA).

Key Points:

· SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA).
Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol “SNWV”.
· This funding is expected to be anchored by investors affiliated with Sweat Equity Partners and Mercury Life Sciences.
· SANUWAVE has two FDA approved medical devices in the wound care space.